These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 8795592)

  • 41. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
    Duddy M; Palace J
    Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
    [No Abstract]   [Full Text] [Related]  

  • 42. Editorial: the pitfalls of combination therapy.
    Vermersch P
    Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
    [No Abstract]   [Full Text] [Related]  

  • 43. The future looks bright.
    Wende KE
    Rehab Manag; 1999; 12(2):32-4. PubMed ID: 10350900
    [No Abstract]   [Full Text] [Related]  

  • 44. Misdiagnosis of multiple sclerosis and beta-interferon.
    Poser CM
    Lancet; 1997 Jun; 349(9069):1916. PubMed ID: 9217787
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
    Tsareva E; Kulakova O; Boyko A; Favorova O
    Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract]   [Full Text] [Related]  

  • 47. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
    Giacomini PS; Arnold DL; Bar-Or A; Antel JP
    Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
    [No Abstract]   [Full Text] [Related]  

  • 48. 'Time is brain' also in multiple sclerosis.
    Freedman MS
    Mult Scler; 2009 Oct; 15(10):1133-4. PubMed ID: 19808740
    [No Abstract]   [Full Text] [Related]  

  • 49. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
    Lim ET; Giovannoni G
    Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Additional indicators of the assessment of efficacy of disease modifying drugs (preliminary results)].
    Iakushina TI; Lizhdvoĭ VIu; Vasilenko IA; Andriukhina OM; Kotov SV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):61-5. PubMed ID: 23528596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of interferon Beta and glatiramer acetate in multiple sclerosis.
    Goodin DS
    Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early treatment.
    Comi G
    Neurol Sci; 2006 Mar; 27 Suppl 1():S8-12. PubMed ID: 16708191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Designing rational therapies for multiple sclerosis.
    Steinman L; Conlon P
    Biotechnology (N Y); 1995 Feb; 13(2):118-20. PubMed ID: 9678929
    [No Abstract]   [Full Text] [Related]  

  • 55. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta.
    McDonald WI; Miller DH; Thompson AJ
    Ann Neurol; 1994 Jul; 36(1):14-8. PubMed ID: 8024255
    [No Abstract]   [Full Text] [Related]  

  • 56. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
    Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Placebo? no thanks, it might be bad for me!
    Garattini S; Bertelé V; Banzi R
    Eur J Clin Pharmacol; 2013 Mar; 69(3):711-4. PubMed ID: 22983310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.
    ; Wiendl H; Toyka KV; Rieckmann P; Gold R; Hartung HP; Hohlfeld R
    J Neurol; 2008 Oct; 255(10):1449-63. PubMed ID: 19005625
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy in multiple sclerosis, Part 2.
    Becker CC; Gidal BE; Fleming JO
    Am J Health Syst Pharm; 1995 Oct; 52(19):2105-20; quiz 2132-4. PubMed ID: 8535945
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.
    Costello F; Stüve O; Weber MS; Zamvil SS; Frohman E
    Curr Opin Neurol; 2007 Jun; 20(3):281-5. PubMed ID: 17495621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.